CC BY-NC-ND 4.0 · Thromb Haemost 2019; 119(07): 1084-1093
DOI: 10.1055/s-0039-1688687
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Joanne I. Adamkewicz
1  Genentech, Inc., South San Francisco, California, United States
,
David C. Chen
1  Genentech, Inc., South San Francisco, California, United States
,
Ido Paz-Priel
1  Genentech, Inc., South San Francisco, California, United States
› Author Affiliations
Funding This work was financially supported by F. Hoffmann-La Roche, Ltd.
Further Information

Publication History

15 October 2018

19 March 2019

Publication Date:
07 May 2019 (eFirst)

  

Abstract

Emicizumab bridges activated factor IX (FIX) and FX to restore the tenase function mediated by activated FVIII (FVIIIa), which is deficient in people with haemophilia A (PwHA). Unlike FVIII, emicizumab does not require activation to function; thus, in coagulation assays, the behavior of emicizumab may differ from that of FVIII. The objective of this study was to assess the effect of emicizumab on coagulation assays, including potential interference behavior that may produce inaccurate or misleading results. A variety of clotting-based, amidolytic/chromogenic, latex particle-enhanced turbidometric, and enzyme-linked immunosorbent methods were investigated. As expected based on its pharmacologic mechanism of action, emicizumab exhibited strong activity on the activated partial thromboplastin time (aPTT), which resulted in interference with several aPTT-based assays, most importantly the one-stage FVIII activity assay; these assays are not recommended for PwHA receiving emicizumab therapy. Pharmacodynamic activity of emicizumab, as measured by FVIII chromogenic assays, was species-dependent due to the binding specificity of the drug antibody. Outside of FVIII assays, emicizumab did not interfere with assays based on immunologic or chromogenic principles, nor with clotting assays based on nonintrinsic pathway activators, thus offering alternative choices where aPTT-based assays might otherwise be used. The observed interferences are in line with the unique mechanism of action of emicizumab. Potential interferences should be taken into account in the selection of coagulation assays and interpretation of coagulation assay test results for PwHA receiving emicizumab therapy.

Note

Investigations were performed at Menal GmbH, Emmendingen, Germany.


Supplementary Material